ID27069A - PHARMACEUTICAL PROPERTIES FOR SELECTING ESTROGEN DEFFICIENT SUPPLEMENTS IN THE NERVOUS CENTER SYSTEM - Google Patents
PHARMACEUTICAL PROPERTIES FOR SELECTING ESTROGEN DEFFICIENT SUPPLEMENTS IN THE NERVOUS CENTER SYSTEMInfo
- Publication number
- ID27069A ID27069A IDW20001592A ID20001592A ID27069A ID 27069 A ID27069 A ID 27069A ID W20001592 A IDW20001592 A ID W20001592A ID 20001592 A ID20001592 A ID 20001592A ID 27069 A ID27069 A ID 27069A
- Authority
- ID
- Indonesia
- Prior art keywords
- transcription
- central nervous
- estradiol
- oestrogen
- nervous system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Selected steroids are used to produce pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system (CNS) without influencing other organs or systems. These steroids are characterised in that they have a selective, neurotropic, oestrogen-like transcription effect, unlike the systemically active natural and synthetic oestrogens, including 17a-estradiol. It has been surprisingly discovered that the selected steroids, when used according to the invention, selectively influence the transcription of oestrogen-dependent genes in the central nervous system and cause alterations of the corresponding physiological parameters; have transcription effects specific to the central nervous systems in doses which have no biological effects on the tissues of the reproductive system; have transcription effects specific to the central nervous system at doses at which neither 17b-estradiol nor 17a-estradiol have any effect; and do not influence the transcription of oestrogen-dependent genes in the central nervous system to a greater extent than the secondary 17b-estradiol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19807264 | 1998-02-20 | ||
| DE1998121831 DE19821831A1 (en) | 1998-05-15 | 1998-05-15 | Selectively supplementing estrogen deficiency in the central nervous system, using 14,15-cyclopropano estrane steroid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID27069A true ID27069A (en) | 2001-02-22 |
Family
ID=26044035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDW20001592A ID27069A (en) | 1998-02-20 | 1999-02-10 | PHARMACEUTICAL PROPERTIES FOR SELECTING ESTROGEN DEFFICIENT SUPPLEMENTS IN THE NERVOUS CENTER SYSTEM |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1056460B1 (en) |
| JP (1) | JP2002503694A (en) |
| KR (1) | KR20010041107A (en) |
| CN (1) | CN1291102A (en) |
| AT (1) | ATE252388T1 (en) |
| AU (1) | AU739071C (en) |
| BG (1) | BG104689A (en) |
| BR (1) | BR9909205A (en) |
| CA (1) | CA2321498A1 (en) |
| CZ (1) | CZ291764B6 (en) |
| DE (1) | DE59907446D1 (en) |
| EA (1) | EA002707B1 (en) |
| EE (1) | EE03906B1 (en) |
| HU (1) | HUP0100742A3 (en) |
| ID (1) | ID27069A (en) |
| IL (1) | IL137727A0 (en) |
| IS (1) | IS5571A (en) |
| NO (1) | NO20004153L (en) |
| NZ (1) | NZ506049A (en) |
| PL (1) | PL342313A1 (en) |
| SK (1) | SK12152000A3 (en) |
| TR (1) | TR200002400T2 (en) |
| UA (1) | UA57830C2 (en) |
| WO (1) | WO1999042108A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2253318T3 (en) * | 2001-11-07 | 2006-06-01 | Schering Ag | IN VITRO LIGAND CROSSING OF THE STROGEN RECEIVER. |
| CN112189624A (en) * | 2020-09-08 | 2021-01-08 | 山东第一医科大学(山东省医学科学院) | Method for constructing and identifying female AD model by using receptor gene silencing technology |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791099A (en) * | 1984-10-29 | 1988-12-13 | Chaovanee Aroonsakul | Method of treatment for central nervous system diseases such as Alzheimer's's disease |
| US4897389A (en) * | 1984-10-29 | 1990-01-30 | Chaovanee Aroonsakul | Treating central nervous system diseases |
| DE4239946C2 (en) * | 1992-11-27 | 2001-09-13 | Jenapharm Gmbh | Estrane derivatives with a 14alpha, 15alpha-methylene group and process for their preparation |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| DE4338314C1 (en) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage |
| DE4429397C2 (en) * | 1994-08-09 | 2003-11-20 | Jenapharm Gmbh | Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds |
| DE19524937A1 (en) * | 1995-07-08 | 1997-01-09 | Jenapharm Gmbh | Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage and for drug substitution in men |
| AU6507996A (en) * | 1995-07-24 | 1997-02-18 | University Of Florida Research Foundation, Inc. | Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells |
-
1999
- 1999-02-10 DE DE59907446T patent/DE59907446D1/en not_active Expired - Fee Related
- 1999-02-10 ID IDW20001592A patent/ID27069A/en unknown
- 1999-02-10 EE EEP200000477A patent/EE03906B1/en not_active IP Right Cessation
- 1999-02-10 NZ NZ506049A patent/NZ506049A/en unknown
- 1999-02-10 JP JP2000532123A patent/JP2002503694A/en not_active Abandoned
- 1999-02-10 KR KR1020007009148A patent/KR20010041107A/en not_active Application Discontinuation
- 1999-02-10 EP EP99910118A patent/EP1056460B1/en not_active Expired - Lifetime
- 1999-02-10 AU AU29209/99A patent/AU739071C/en not_active Ceased
- 1999-02-10 PL PL99342313A patent/PL342313A1/en unknown
- 1999-02-10 AT AT99910118T patent/ATE252388T1/en not_active IP Right Cessation
- 1999-02-10 WO PCT/DE1999/000353 patent/WO1999042108A1/en not_active Application Discontinuation
- 1999-02-10 CA CA002321498A patent/CA2321498A1/en not_active Abandoned
- 1999-02-10 IL IL13772799A patent/IL137727A0/en unknown
- 1999-02-10 HU HU0100742A patent/HUP0100742A3/en unknown
- 1999-02-10 EA EA200000858A patent/EA002707B1/en not_active IP Right Cessation
- 1999-02-10 SK SK1215-2000A patent/SK12152000A3/en unknown
- 1999-02-10 BR BR9909205-0A patent/BR9909205A/en not_active IP Right Cessation
- 1999-02-10 CN CN99803170A patent/CN1291102A/en active Pending
- 1999-02-10 CZ CZ20002938A patent/CZ291764B6/en not_active IP Right Cessation
- 1999-02-10 TR TR2000/02400T patent/TR200002400T2/en unknown
- 1999-10-02 UA UA2000095399A patent/UA57830C2/en unknown
-
2000
- 2000-07-24 IS IS5571A patent/IS5571A/en unknown
- 2000-08-15 BG BG104689A patent/BG104689A/en unknown
- 2000-08-18 NO NO20004153A patent/NO20004153L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200000858A1 (en) | 2001-04-23 |
| HUP0100742A2 (en) | 2001-09-28 |
| CA2321498A1 (en) | 1999-08-26 |
| SK12152000A3 (en) | 2001-02-12 |
| JP2002503694A (en) | 2002-02-05 |
| AU739071B2 (en) | 2001-10-04 |
| EE200000477A (en) | 2001-12-17 |
| NZ506049A (en) | 2002-09-27 |
| ATE252388T1 (en) | 2003-11-15 |
| IS5571A (en) | 2000-07-24 |
| EE03906B1 (en) | 2002-12-16 |
| PL342313A1 (en) | 2001-06-04 |
| EP1056460A1 (en) | 2000-12-06 |
| AU739071C (en) | 2002-04-11 |
| UA57830C2 (en) | 2003-07-15 |
| BG104689A (en) | 2001-04-30 |
| NO20004153L (en) | 2000-10-09 |
| BR9909205A (en) | 2000-11-14 |
| EA002707B1 (en) | 2002-08-29 |
| AU2920999A (en) | 1999-09-06 |
| CN1291102A (en) | 2001-04-11 |
| IL137727A0 (en) | 2001-10-31 |
| CZ291764B6 (en) | 2003-05-14 |
| CZ20002938A3 (en) | 2001-01-17 |
| WO1999042108A1 (en) | 1999-08-26 |
| KR20010041107A (en) | 2001-05-15 |
| TR200002400T2 (en) | 2000-11-21 |
| DE59907446D1 (en) | 2003-11-27 |
| NO20004153D0 (en) | 2000-08-18 |
| HUP0100742A3 (en) | 2002-07-29 |
| EP1056460B1 (en) | 2003-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998027929A3 (en) | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | |
| WO1996019568A3 (en) | Stabilized ribozyme analogs | |
| HUP0102483A2 (en) | Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol | |
| TR199800648A1 (en) | Medication system for two or more active ingredients. | |
| AU2561195A (en) | Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding | |
| CA2337991A1 (en) | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | |
| MY137435A (en) | Retinoid compounds (i) | |
| ATE381533T1 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR USE | |
| ID27069A (en) | PHARMACEUTICAL PROPERTIES FOR SELECTING ESTROGEN DEFFICIENT SUPPLEMENTS IN THE NERVOUS CENTER SYSTEM | |
| NZ333232A (en) | Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease | |
| BG102660A (en) | Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders | |
| WO2001085165A3 (en) | Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system | |
| ES2110258T3 (en) | DERIVATIVES OF 1,3,5 (10) -STRATRIENE ASSETS BY ORAL WAY. | |
| ATE286739T1 (en) | USE OF A COMPOUND CONTAINING POLLEN EXTRACT TO TREAT DISEASE-RELATED WEIGHT GAIN | |
| CA2248841A1 (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
| BR0113618A (en) | 17-methylene steroids, processes for their preparation and pharmaceutical compositions containing these compounds | |
| Cadman | Roche brings new formulation of saquinavir to FDA. Food and Drug Administration | |
| DE59803623D1 (en) | 11BETA-ARYL-SUBSTITUTED 14,17-ETHANO ESTRATRIENE, METHOD FOR THE PRODUCTION OF THESE COMPOUNDS AND THEIR USE FOR THE PRODUCTION OF MEDICINAL PRODUCTS | |
| 陈春富 et al. | Measurement of platelet membrane fluidity in patients with Binswanger's disease or Alzheimer's disease | |
| MX9600140A (en) | Use of vitamin e tocopheryl derivatives in ophthalmic compositions. |